-
Researchers who have closely studied the United States' national HIV/AIDS prevention strategy as it has developed over the past three decades have concluded that it has been underfunded, and it's very difficult to implement.
-
HIV/AIDS mortality data highlight disparities between states, suggesting differences in HIV treatment and care, a new study shows.1
-
The American Medical Association recently voted to support amending a federal law that bars clinical research of HIV-infected organ donation, as a potentially lifesaving measure for people living with HIV infection.
-
One obstacle to the success of the U.S. national HIV/AIDS strategy involves the accuracy of metrics used for monitoring HIV care, including late diagnoses and linkage to sustained care, a new study notes.
-
Thirty years after the world first became aware of a strange syndrome that caused young men to acquire rare diseases like Pneumocystis carinii pneumonia (PCP) and Kaposi's Sarcoma, nations across the globe continue to battle against the HIV/AIDS epidemic.
-
Updates to the darunavir (Prezista®) package insert, specifically sections: 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on Oct. 19, 2011, to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, "A randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects."
-
A total of 783 children 6-24 months of age were followed for an entire respiratory season by four experienced otoscopists using pneumatic otoscopy of one ear, randomly selected for each child.
-
Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxifloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy clinical trial design.
-
Baseline production of PSMa subtypes was examined in 50 PVL-positive methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA clinical isolates using liquid chromatography-tandem mass spectrometry (LC-MS-MS), and these results were compared to a control strain, LAC (USA300). MICs were determined using a broth macrodilution method.
-
A double-blind, randomized, controlled trial conducted by the International Neonatal Immunotherapy Study (INIS) compared adjunctive therapy of human nonspecific polyvalent IgG intravenous immune globulin to placebo in the treatment of newborn infants with suspected or proven sepsis who were also receiving antibiotic therapy.
